

University of Guelph; and Overall Team—University of Guelph.

- Undergraduate Division: Live Assessment High Scoring Individual—Samantha Likar, University of Minnesota; Live Assessment High Scoring Team—Texas A&M University; Overall Individual—Ashley Dunn, Michigan State University; and Overall Team—Michigan State University Team 1.

“We’re excited that this event continues to draw more and more participants every year. It’s a great indication of the leadership role veterinarians play—and will continue to play—in protecting animals’ welfare,” said AVMA President John Howe.

“These dedicated future veterinarians and animal scientists have worked hard to prepare for this contest, and the things they’ve learned and the connections they’ve made this past weekend will help position them for great success in their future careers,” he said.

The next two Animal Welfare Assessment Contests will be held at North Carolina State University, followed by contests in 2022 and 2023 at the University of Wisconsin-River Falls.

Learn more about the Animal Welfare Assessment Contest at AWJAC.org. 🍷

WHO: VACCINE MAKES EBOLA PREVENTABLE

A vaccine against the most deadly strain of Ebola virus meets international agencies’ standards, giving hope it could reduce the toll of outbreaks.

World Health Organization officials said Nov. 12, 2019, that Merck’s injectable human-use vaccine against Ebola Zaire virus meets the organization’s standards for quality, safety, and efficacy. That determination lets United Nations’ agencies and the organization Gavi, the Vaccine Alliance, buy it for use in at-risk countries.

One day earlier, Merck officials announced that the European Commission had granted a conditional marketing authorization for the vaccine, which allows its use in European Union countries.

In an announcement, WHO Director-General Tedros Adhanom Ghebreyesus called the WHO’s declaration a historic step.

“Five years ago, we had no vaccine and no therapeutics for Ebola,” he said. “With a prequalified vaccine and experimental therapeutics, Ebola is now preventable and treatable.”

Kenneth C. Frazier, chairman and CEO of Merck, said in a company announcement that the vaccine, Ervebo, is a product of unprecedented collaboration and should be a global source of pride. He noted that the vaccine is under review by other agencies, including the U.S. Food and Drug Administration.

“We at Merck are honored to play a part in Ebola outbreak response efforts and we remain committed to our partners and the people we serve,” he said. “We also look forward to continuing to work with the FDA and the African countries on their regulatory reviews over the coming months and with the World Health Organization on vaccine prequalification, which will help broaden access to this important vaccine for those who need it most.”

Merck will make the vaccine at a plant in Germany, and licensed doses will be available starting in the third quarter of 2020, the company announcement states. 🍷

CORRECTIONS

The article “Honor Roll members inducted” in the Jan. 1, 2020, issue of *JAVMA* News, page 27, incorrectly listed the new AVMA honor roll members from Tennessee under the heading for South Dakota. The correct list is as follows.

SOUTH DAKOTA

Carl R. Johnson, Sturgis

Regg D. Neiger, Arlington

Gerald B. Teachout, Yankton

TENNESSEE

Robert C. DeNovo, Knoxville

Jerry B. Flatt, Cookeville

Heber S. Johnston, Cordova

William B. Miesse, Big Sandy

Richard J. Rahija, Collierville

Margaret S. Swartout, Knoxville

Doris L. Whitton, Hendersonville

The article “Allergic to work” in the Jan. 1, 2020, issue of *JAVMA* News, page 22, gave an incorrect first name for Dr. Jessica Graves. 🍷